This is a good start, Sanofi are global behemoths clearly liking...

This is a good start, Sanofi are global behemoths clearly liking what they see and want to explore a commercial deal.

The option is for a consumer facing application, unlikely to be used in a telehealth setting.

Another company with a breakthrough platform technology I’m invested in is also taking a similar route, negotiating their technology for a single vertical and geography. It's a way of keeping the big multinationals honest and transparent.

Giving global rights to a single company for ‘x’ amount can stall a rollout. A technology like ResApp’s needs multiple commercial partners across different verticals to fast track to market.